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OBJECTIVES We sought to assess the effects of brain natriuretic peptide (BNP) on systemic and regional
sympathetic nervous activity (SNA) in both patients with congestive heart failure (CHF) and
healthy control subjects.
BACKGROUND Although the response of SNA to atrial natriuretic peptide (ANP) has been well documented,
the response of SNA to BNP is largely unknown.
METHODS We assessed cardiac and whole-body SNA using the norepinephrine (NE) tracer dilution
method before and after infusion of two doses of BNP (3 and 15 ng/kg body weight per min)
in 11 patients with stable CHF (ejection fraction 24 6 2%) and 12 age-matched healthy
control subjects. In addition, renal SNA and hemodynamic variables were assessed at baseline
and after the higher BNP dose.
RESULTS Low dose BNP did not change blood pressure or whole-body NE spillover, but reduced
cardiac NE spillover in both groups by 32 6 13 pmol/min (p , 0.05). In both groups, high
dose BNP reduced pulmonary capillary pressure by 5 6 1 mm Hg (p , 0.001) and mean
arterial pressure by 6 6 3 mm Hg (p , 0.05), without a concomitant increase in whole-body
NE spillover; however, cardiac NE spillover returned to baseline levels. Renal NE spillover
remained virtually unchanged in healthy control subjects (501 6 120 to 564 6
115 pmol/min), but was reduced in patients with CHF (976 6 133 to 656 6 127 pmol/min,
p , 0.01).
CONCLUSIONS Our results demonstrate a sympathoinhibitory effect of BNP. Cardiac sympathetic inhibition
was observed at BNP concentrations within the physiologic range, whereas high dose BNP,
when arterial and filling pressures fell and reflex sympathetic stimulation was expected,
systemic and cardiac SNA equated to baseline values. There was inhibition of renal SNA in
patients with CHF, but not in healthy control subjects. Whether this effect is specific to BNP
or related to reduced filling pressure remains to be determined. (J Am Coll Cardiol 2001;37:
1221–7) © 2001 by the American College of Cardiology
With the progression of congestive heart failure (CHF),
various neurohumoral systems, including the renin-
angiotensin-aldosterone system (RAAS), sympathetic ner-
vous system (SNS) and natriuretic peptides (NP), are
activated (1). Although the RAAS and SNS contribute to
the progression of CHF, NP are thought to be beneficial by
counteracting vasoconstriction and water and salt retention
(2). Atrial natriuretic peptide (ANP) and brain natriuretic
peptide (BNP) have a spectrum of biologic actions poten-
tially favorable in CHF, including diuretic, natriuretic and
hypotensive properties, as well as inhibition of the RAAS
and of endothelin secretion (3–5). It has been suggested that
BNP is a more slowly responding but more powerful
hormone than ANP in terms of improving cardiovascular
function in CHF. Thus, infusion of BNP has been proposed
as a novel therapy for CHF (6,7).
Although some studies observed that ANP might in-
crease sympathetic activity (8,9), the majority reported a
suppressive effect of ANP on the SNS (10–13). The effects
of BNP on sympathetic activity, however, are largely un-
known, as they have not been investigated directly in
humans, and indirect evidence derived from plasma norepi-
nephrine (NE) was not conclusive (14,15). In CHF, cardiac
stimulation and renal sympathetic stimulation are very
important, as they precede generalized sympathetic activa-
tion (16), and cardiac sympathetic activation contributes to
a poor prognosis (17). The effect of NP on regional
sympathetic activity is largely unknown, and in this study,
we investigated the effect of exogenous BNP on the cardiac,
renal and whole-body sympathetic activity in patients with
CHF as compared with normal control subjects.
METHODS
Study group. The study group comprised 11 patients (age
58 6 4 years) with stable CHF. Patients had a left
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ventricular ejection fraction ,40% (mean 24 6 2%), as
assessed by radionuclide ventriculography, secondary to
coronary artery disease in nine patients and dilated cardio-
myopathy in two patients. All patients were taking
angiotensin-converting enzyme inhibitors; diuretics (n 5 8);
digoxin (n 5 7); nitrates (n 5 4); amiodarone (n 5 4); and
beta-blockers (n 5 5).
Twelve healthy control subjects of comparable age (mean
52 6 2 years) were recruited from the Health Care Centre
of the Baker Medical Research Institute, where they at-
tended screening for heart risk factors. All were free of a
history of cardiovascular disease; they had no cardiovascular
risk factors; and none were receiving long-term drug ther-
apy. Clinical examination, laboratory testing (e.g., electro-
lytes, liver and kidney function, blood lipids, blood cell
count) and the electrocardiogram were normal in all pa-
tients. Healthy control subjects underwent the same proce-
dures, apart from radionuclide measurement of ejection
fraction, as did patients with CHF. The protocol was
approved by the Ethics Review Committee of the Alfred
Hospital, and patients and healthy control subjects gave
written, informed consent to participate in the study.
Study schedule. The subjects were studied in the morning;
they did not have tea or coffee overnight. A 3F cannula was
inserted into a radial artery for blood pressure monitoring
and blood sampling. Thereafter, an 8F sheath was inserted
into the right internal jugular vein in patients with CHF,
and into the medial antecubital vein of either arm in healthy
control subjects. Catheters were advanced and exchanged
through the same sheath. Pulmonary artery pressure mea-
surements (mean and wedge) were recorded by using a
Swan-Ganz catheter. Cardiac output was measured by
thermodilution. Hemodynamic measurements were impos-
sible in three healthy control subjects for technical reasons.
After the hemodynamic evaluation, a Cournand catheter
was placed under fluoroscopic guidance in one of the renal
veins for blood sampling. Renal plasma flow was measured
using p-aminohippurate clearance. Arterial versus renal vein
concentrations of p-aminohippurate were determined using
steady-state infusion into a peripheral vein. Thereafter, a
thermodilution catheter (Webster CCS 7/8U 90A, Cordis
Corp., Miami, Florida) was placed under fluoroscopic guid-
ance in the coronary sinus and was used to sample coronary
sinus blood and to measure coronary sinus blood flow.
Coronary sinus plasma flow was calculated using the sub-
ject’s hematocrit.
After completion of the baseline measurements, a loading
dose of BNP (100 ng/kg body weight over 5 min; human
BNP, Bachem, Switzerland) was given intravenously, fol-
lowed by a infusion of 3 ng/kg per min for 25 min.
Thereafter, blood sampling and blood flow measurement in
the coronary sinus were repeated. Then, a second loading
dose of BNP (400 ng/kg given over 5 min) was followed by
an infusion of 15 ng/kg per min for 25 min. Blood flow
measurement and blood sampling in the coronary sinus were
repeated. Subsequently, the Cournand catheter was rein-
serted into the same renal vein for blood sampling, which
was not possible in one patient with CHF and one healthy
subject. Finally, the Swan-Ganz catheter was reinserted for
hemodynamic measurements. Thus, whole-body and car-
diac NE spillover were assessed at baseline and after each
dose of infused BNP, whereas renal SNS and hemodynamic
data were measured at baseline and after the high dose of
BNP only.
Estimation of sympathetic activity. Measurements of the
spillover of NE to plasma from the heart, kidneys and body
as a whole were used to estimate regional and systemic
sympathetic activity (18). All patients received an intrave-
nous infusion of tritiated levo-NE (New England Nuclear,
Boston, Massachusetts; 0.5 to 1.5 mCi/min). Arterial and
venous blood samples were drawn simultaneously at least
30 min after the start of radiotracer infusion. Plasma was
separated by centrifugation at 4°C and stored at 280°C
until analysis.
The total (SPNEtot) and regional (SPNEreg) NE spillover
(SP) rates to the plasma were measured by using methods
developed by Esler et al. (18):
SPNEtot 5
[3H]NEin
SANE
where [3H]NEin is the [
3H]NE infusion rate, and SANE is
the specific activity of plasma NE.
SPNEreg 5 ([NEV 2 NEA] 1 [NEA 3 ER]) 3 QP
where NEV and NEA are the venous (either cardiac or renal)
and arterial plasma NE concentrations, respectively; ER is
the fractional extraction of tracer NE across the heart and
kidneys; and Q P is the regional plasma flow.
Assays. Catecholamines in plasma (1 ml) and samples of
the infusion preparation (10 ml) were adsorbed onto alu-
mina and quantified by liquid chromatography with elec-
trochemical detection, as previously described (19). Timed
collections of the eluent as it leaves the electrochemical cell
enable separation of [3H]-NE for assay by liquid scintilla-
tion spectrometry.
Plasma levels of BNP. Arterial blood was collected into
chilled tubes containing EDTA and aprotinin (500 KIU/ml
blood) for assessment of plasma BNP. Plasma was separated
immediately using a refrigerated centrifuge and stored at
280°C until measurement. Brain natriuretic peptide was
determined directly, without previous extraction in dupli-
cate by a solid-phase immunometric radioimmunoassay
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
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using 125labeled BNP antibody (Shionogi Chemical Co.,
Osaka, Japan).
Statistical analysis. Data are expressed as the mean value 6
SEM. Baseline characteristics were compared between the two
groups using the independent samples t test. Two-way analysis
of variance for repeated measures was used to test the responses
to the BNP infusions. Spearman rank correlation was used to
assess the relationship between baseline values and changes
after BNP infusion of NE spillover. A p value #0.05 was
considered to show a statistically significant difference. Anal-
yses were performed using the statistical package SPSS for
Windows 9.0.
RESULTS
The baseline characteristics of the patients and control
subjects are summarized in Table 1. Patients with CHF had
elevated filling pressures and a reduced cardiac index, as
compared with healthy control subjects. The SNS was
activated in patients with CHF, although the differences in
cardiac NE spillover failed to reach statistical significance.
The baseline BNP concentration was significantly elevated
in patients with CHF.
Infusion of BNP resulted in a significant (p , 0.001)
increase in the arterial BNP concentration in both healthy
subjects (8 6 2 to 31 6 5 to 188 6 44 pmol/liter) and
patients with CHF (67 6 15 to 138 6 15 to 520 6 80
pmol/liter). A lesser increase in clearance and maintained
production of BNP (data not shown) caused a larger
increase in arterial BNP levels in patients with CHF (p ,
0.001).
Hemodynamic response to BNP. There was no change in
blood pressure with the lower BNP dose in both patients
with CHF and control subjects (systolic: 21.7 6 1.2 and
0.0 6 2.5 mm Hg; mean: 21.1 6 1.0 and 1.2 6
1.5 mm Hg; diastolic: 20.7 6 1.4 and 1.7 6 1.3 mm Hg,
respectively; all p . 0.1). Heart rate also did not change in
patients with CHF or control subjects (21.0 6 1.2 beats/
min and 22.1 6 1.4 beats/min, respectively; both p . 0.1).
Figure 1 depicts the hemodynamic responses to high dose
BNP. There was a significant reduction in cardiac filling
pressures in both groups. However, pulmonary artery and
capillary wedge pressures fell more in patients with CHF
(p , 0.05). A fall in diastolic pressure was evident in the
CHF group only, but the fall in systolic pressure did not
Table 1. Baseline Characteristics of Patients With Congestive Heart Failure and Healthy
Control Subjects
Patients With CHF
(n 5 11)
Control Subjects
(n 5 12)
p
Value
Heart rate (beats/min) 76 6 6 68 6 3 0.1
MAP (mm Hg) 88 6 4 97 6 3 0.06
RAP (mm Hg) 6.9 6 0.7 4.8 6 0.5 0.05
PAP (mm Hg) 26.9 6 2.7 12.7 6 0.6 0.001
PCWP (mm Hg) 18.3 6 2.2 7.3 6 0.6 0.001
CI (liters/m2 per min) 2.49 6 0.15 3.13 6 0.17 0.01
SVR (dynepcm25ps) 1,363 6 129 1,322 6 133 . 0.1
PVR (dynepcm25ps) 145 6 17 73 6 8 0.001
Arterial NE (nmol/liter) 2.17 6 0.34 1.54 6 0.19 0.1
Body NE SP (nmol/min) 7.43 6 1.32 4.04 6 0.42 0.05
Cardiac NE SP (nmol/min) 0.250 6 0.051 0.170 6 0.025 0.1
Coronary sinus NE (nmol/liter) 3.17 6 0.60 1.85 6 0.30 0.05
Renal NE SP (nmol/min) 0.967 6 0.127 0.502 6 0.100 0.005
Renal vein NE (nmol/liter) 3.92 6 0.56 1.75 6 0.25 0.005
BNP (pmol/liter) 66.7 6 15.3 7.8 6 1.7 0.001
Data are presented as the mean value 6 SEM.
BNP 5 brain, or b-type, natriuretic peptide; CHF 5 congestive heart failure; CI 5 cardiac index; MAP 5 mean arterial
pressure; NE 5 norepinephrine; PAP 5 pulmonary artery pressure; PCWP 5 pulmonary capillary wedge pressure; PVR 5
pulmonary vascular resistance; RAP 5 right atrial pressure; SP 5 spillover; SVR 5 systemic vascular resistance.
Figure 1. Hemodynamic data in patients with CHF as compared with
healthy subjects before (B) and after (BNP) infusion of BNP (15 ng/kg per
min). *p , 0.05 between groups; §p , 0.05 after BNP infusion versus
baseline; †p , 0.05 response to BNP between different groups. BNP 5
brain, or b-type, natriuretic peptide; CHF 5 congestive heart failure; CI 5
cardiac index; DP 5 diastolic pressure; HR 5 heart rate; PAP 5
pulmonary artery pressure; PCWP 5 pulmonary capillary wedge pressure;
RA 5 right atrial (pressure).
1223JACC Vol. 37, No. 5, 2001 Brunner-La Rocca et al.
April 2001:1221–7 Effects of BNP on Sympathetic Nervous Activity
differ between the two groups (CHF vs. control: 210.3 6
3.3 vs. 28.1 6 6.5 mm Hg). There was a significant
reduction in the cardiac index in healthy control subjects,
whereas it did not change in patients with CHF. There were
only minor changes in systemic vascular resistance (CHF vs.
control: 29 6 8% vs. 5 6 8%; both p . 0.1), and no change
in pulmonary vascular resistance. Although renal plasma
flow fell in both groups (CHF vs. control: from 682 6 80 to
514 6 61 ml/min vs. from 787 6 73 to 627 6 51 ml/min;
both p , 0.01), coronary sinus blood flow did not change
significantly.
Effects of BNP on SNS. Figure 2 depicts the responses of
whole-body, cardiac and renal NE spillover to BNP infu-
sions. Whole-body NE spillover tended to decrease in
response to the lower BNP dose in both groups; in healthy
subjects, it returned to baseline values with the higher dose,
whereas in patients with CHF, it remained low. Cardiac
NE spillover was similarly and significantly reduced in both
groups by the lower BNP dose (p , 0.05), but returned to
baseline values with the higher dose. Renal NE spillover
rose slightly with the higher BNP dose in healthy control
subjects (p . 0.1), but decreased significantly in patients
with CHF (p , 0.01). Similarly, the renal venous NE
concentration tended to rise in healthy control subjects
(from 1.75 6 0.25 to 1.92 6 0.30 nmol/liter, p . 0.1), but
fell significantly in patients with CHF (3.92 6 0.56 to
3.08 6 0.65 nmol/liter, p , 0.05).
There was a negative correlation between baseline NE
spillover and its reduction after BNP infusion in both
groups combined (whole body: r 5 20.46, p , 0.05;
cardiac: r 5 20.42, p , 0.05; renal: r 5 20.58, p , 0.01)
(Fig. 3). The sympathetic response was not correlated with
changes in filling and arterial pressures, nor with the
medication in patients with CHF.
DISCUSSION
Our study shows that BNP may inhibit the SNS, an effect
mostly apparent if the sympathetic activity at rest was
elevated. In addition, to the best of our knowledge, we are
the first to measure the response of renal sympathetic
activity in humans during infusion of NP and to demon-
strate suppression of renal sympathetic activity by BNP in
patients with CHF. Moreover, BNP infusion at doses
leading to increases in circulating BNP in the physiologic
range resulted in a reduction in cardiac sympathetic activity
in both healthy control subjects and patients with CHF.
Effects of BNP on SNS. After the higher BNP dose, the
reduction in arterial and cardiac filling pressures, which
would be expected to unload cardiopulmonary and arterial
baroreceptors, did not result in the expected reflex increase
in whole-body NE spillover, suggesting a relative sympa-
thoinhibitory action of BNP. We did not directly compare
BNP with a vasodilating agent, such as sodium nitroprus-
side or nitroglycerin, but these agents have consistently been
shown to significantly increase systemic sympathetic activity
in both healthy control subjects and patients with CHF
(9,10,20–23). In addition, studies investigating the effects
of reduction in cardiac filling pressures by lower body,
Figure 2. Whole-body (top panel), cardiac (middle panel) and renal
(bottom panel) NE SP in patients with CHF as compared with healthy
subjects before (B) and after the lower (BNP1) and higher (BNP2) BNP
dose. *p , 0.05 between groups; §p , 0.05 after BNP infusion versus
baseline; †p , 0.05 response to BNP between different groups. BNP 5
brain, or b-type, natriuretic peptide; CHF 5 congestive heart failure;
NE 5 norepinephrine; SP 5 spillover.
Figure 3. Scatter plots of changes in cardiac (top panel; lower BNP dose),
whole-body (middle panel; lower BNP dose) and renal (bottom panel;
higher BNP dose) NESP in relation to baseline levels in both groups. The
“r” values are rank correlations. BNP 5 brain, or b-type, natriuretic peptide;
CHF 5 congestive heart failure; NESP5 norepinephrine spillover.
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negative pressure described stimulation of the systemic SNS
in healthy subjects (8,10,24). Reductions in both central
venous and diastolic blood pressure, similar to those ob-
served in our study, by the combination of nitroglycerin and
lower body, negative pressure resulted in a distinct increase
in muscular SNS in patients with CHF (11). In contrast,
with BNP, whole-body NE spillover tended to fall in our
patients with CHF.
A significant reduction of renal sympathetic activity was
observed in the patients with CHF. This is of potential
therapeutic importance, because elevation of renal sympa-
thetic activity plays an important role in the pathophysiol-
ogy of CHF (16). Activation of the renal SNS stimulates
the RAAS (25), one of the key pathophysiologic mecha-
nisms in CHF, and directly promotes sodium and water
retention (26). In contrast, renal sympathetic activity tended
to increase in healthy control subjects in the present study.
There are no data on the effect of baroreflex stimulation on
renal sympathetic activity in humans, but in animal studies,
the increase in renal sympathetic activity with direct-acting
vasodilators was much greater than our observed increase in
healthy control subjects (27). Nevertheless, our results
cannot answer the question of whether BNP has direct renal
sympathoinhibitory effects, or whether this is an effect
resulting from the lowered filling pressures in patients with
CHF.
Various mechanisms may account for the different re-
sponse of renal sympathetic activity in patients with CHF
and healthy control subjects. Reflex stimulation may be
suppressed in patients with CHF because of reduced barore-
flex sensitivity (20), in particular, that of cardiopulmonary
baroreceptors (28), although intact arterial baroreflex con-
trol has been described in patients with CHF (29). The
inhibitory action of BNP on renin release (30), and conse-
quently angiotensin II formation, might also reduce sym-
pathetic activity. Natriuretic peptides may modulate sym-
pathetic nerve activity by antagonizing the action of
angiotensin II (31). Likewise, cyclic guanosine monophos-
phate may exert a sympathoinhibitory action (32), particu-
larly when angiotensin II is elevated (33).
The response of cardiac sympathetic activity to BNP
infusion was dependent on the dose used and did not differ
between the two groups. At low dose BNP, which did not
affect arterial pressure in our study, cardiac sympathetic
activity fell, supporting direct inhibition of cardiac sympa-
thetic activity by BNP. This may be cardioprotective,
because a high cardiac sympathetic drive is an important
contributor to the progression of disease in CHF (34) and is
a major determinant of prognosis (17).
However, cardiac sympathetic activity no longer re-
mained suppressed when using a moderately high dose of
BNP (i.e., 15 ng/kg per min); rather, it returned to baseline
levels. This may be caused by baroreflex activation, but may
also represent a relative inhibition of cardiac SNS, because
baroreflex unloading results in an increase in cardiac NE
spillover, at least in subjects with normal left ventricular
function (21,24). However, it remains to be investigated
whether BNP has an inhibitory effect on cardiac sympa-
thetic activity in CHF that exceeds the effect of lowering
left-sided filling pressures (22,24).
Regional differentiation of efferent baroreflex regulation
has been described (35), and our data suggest that this may
depend on the activity of the SNS at rest. Thus, renal SNS,
which was significantly stimulated in patients with CHF, as
compared with healthy control subjects, was significantly
inhibited by BNP. In contrast, the cardiac sympathetic
activity response was comparable in both groups, possibly
because cardiac SNS at rest was only mildly activated in
patients with CHF. This is in line with the response to
BNP being related to baseline sympathetic activity (Fig. 3).
Effects of BNP on hemodynamic data. It is beyond doubt
that NP reduce cardiac preload, but the effects of NP on
arterial vasomotion are less certain (6,30,36–38). Increased
cyclic guanosine monophosphate production undoubtedly
results in arterial vasodilation, but there are studies showing
no decrease (38) or even an increase (30,36) in systemic
vascular resistance by NP. The reason for this discrepancy,
as well as the mechanism by which NP might mediate
vasoconstriction, are completely unknown. Notably, the
vasoconstricting response was not found to be mediated by
the autonomic nervous system (30), and previous studies
found a dissociation between the neural and vascular actions
of NP (39). Interestingly, a reduction in systemic vascular
resistance was mainly seen with relatively high doses of NP
(6,7,37,40), whereas low doses were used when neutral or
vasoconstricting effects were found (30,36,38). Moreover,
the effects on vascular conductance may vary by region (30).
In the vasculature of the kidneys, NP act on the afferent
arterioles as a vasodilator, but on the efferent arterioles as
vasoconstrictive agents, thereby increasing the glomerular
filtration rate (41). Thus, it is conceivable that NP may
cause either an increase or a decrease in renal blood flow,
which is in accordance with the discrepant reports of the
effects of NP on renal plasma flow (42,43).
Study limitations. There are some limitations of our study.
We did not include a group of control subjects in whom a
drug was administered to reduce cardiac filling pressures and
arterial pressure, with no direct effects on the SNS. There-
fore, we cannot exclude an indirect sympathoinhibitory
effect of BNP, although this is unlikely to have occurred, at
least in healthy subjects. In advanced CHF, a positive
feedback relationship between pulmonary artery pressure/
filling pressure and cardiac sympathetic activity has been
found (22,24), such that a reduction in sympathetic activity
could be an indirect effect of cardiac filling pressure lowered
by BNP. However, in contrast to our study, elevation of
systemic sympathetic activity was observed in previous
studies where interventions reduced cardiac filling pressures,
irrespective of underlying conditions (9,10,20–23). Also,
cardiac NE spillover was not significantly elevated in our
CHF group. On the one hand, this might explain the
similar response of cardiac NE spillover in both groups,
1225JACC Vol. 37, No. 5, 2001 Brunner-La Rocca et al.
April 2001:1221–7 Effects of BNP on Sympathetic Nervous Activity
with a distinct effect on renal sympathetic activity between
the groups. On the other hand, we cannot exclude an
influence of the medication on our results in patients with
CHF. Although we did not find a statistical interaction with
the medication, a larger study group would have been
necessary to determine smaller influences.
Finally, to avoid further lengthening of an already long
study by additional changes of the catheters, we did not
measure central hemodynamic data and renal sympathetic
activity at the lower rate of BNP infusion. Although
reduced filling pressures with the lower BNP dose cannot be
excluded, this would not explain the inhibitory effects on the
cardiac sympathetic nervous system in healthy control sub-
jects. Moreover, significant hemodynamic changes were not
observed in patients with CHF with this dose of BNP (40).
Nevertheless, we cannot exclude a favorable influence of a
reduction of cardiac filling pressures on cardiac sympathetic
activity in patients with CHF.
Conclusions. The present observations suggest a sympa-
thoinhibitory effect of BNP. In healthy volunteers, there
was cardiac sympathetic inhibition at BNP concentrations
within the physiologic range, whereas at high dose BNP,
when filling pressures fell and reflex sympathetic stimulation
was expected, systemic and regional SNS activity equated to
baseline values. In patients with CHF, as for healthy
subjects, low dose BNP resulted in cardiac sympathetic
inhibition, whereas at a higher dose, there was selective
inhibition of the elevated renal SNS activity and no reflex
stimulation of systemic and cardiac SNS in the face of a fall
in arterial and cardiac filling pressures. Whether this effect
in patients with CHF is due to a direct action of BNP, or
whether it is indirectly related to a reduction in cardiac
filling pressures, remains to be determined.
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